PURPOSE: Our previous study has revealed that EphA2 overexpression is significantly associated with aggressive behavior and poor prognosis in patients with squamous-cell carcinoma of the head and neck (SCCHN). However, the function of EphA2 in tumorigenesis and cervical lymph node metastasis of SCCHN has never been elucidated in vivo. METHODS: EphA2 was knocked down in SCCHN cell lines. CCK-8 assays, fluorescence-activated cell sorting analysis, invasion and migration assays were performed in vitro. In vivo tumorigenicity assays were performed, and the impact on cervical lymph node metastasis was evaluated. RESULTS: The present investigation demonstrated that suppression of EphA2 resulted in a significant inhibition of proliferation, migration, invasion of SCCHN cells in vitro and markedly diminished their tumorigenicity and lymph node metastasis in vivo. CONCLUSIONS: These results suggest that EphA2 plays a critical role in SCCHN growth and metastasis and may be a promising therapeutic target to prevent the progression of SCCHN.
PURPOSE: Our previous study has revealed that EphA2 overexpression is significantly associated with aggressive behavior and poor prognosis in patients with squamous-cell carcinoma of the head and neck (SCCHN). However, the function of EphA2 in tumorigenesis and cervical lymph node metastasis of SCCHN has never been elucidated in vivo. METHODS:EphA2 was knocked down in SCCHN cell lines. CCK-8 assays, fluorescence-activated cell sorting analysis, invasion and migration assays were performed in vitro. In vivo tumorigenicity assays were performed, and the impact on cervical lymph node metastasis was evaluated. RESULTS: The present investigation demonstrated that suppression of EphA2 resulted in a significant inhibition of proliferation, migration, invasion of SCCHN cells in vitro and markedly diminished their tumorigenicity and lymph node metastasis in vivo. CONCLUSIONS: These results suggest that EphA2 plays a critical role in SCCHN growth and metastasis and may be a promising therapeutic target to prevent the progression of SCCHN.
Authors: Jennifer M Brannan; Banibrata Sen; Babita Saigal; Ludmila Prudkin; Carmen Behrens; Luisa Solis; Wenli Dong; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson Journal: Cancer Prev Res (Phila) Date: 2009-11-24
Authors: Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen Journal: J Clin Invest Date: 2008-01 Impact factor: 14.808
Authors: Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood Journal: Cancer Biol Ther Date: 2008-04-19 Impact factor: 4.742
Authors: Xin Zhang; Yanna Liu; Michael Z Gilcrease; Xiao H Yuan; Gary L Clayman; Karen Adler-Storthz; Zhuo Chen Journal: Cancer Date: 2002-10-15 Impact factor: 6.860
Authors: Marieta I Toma; Kati Erdmann; Michael Diezel; Matthias Meinhardt; Stefan Zastrow; Susanne Fuessel; Manfred P Wirth; Gustavo B Baretton Journal: PLoS One Date: 2014-07-15 Impact factor: 3.240
Authors: Ghazal Efazat; Metka Novak; Vitaliy O Kaminskyy; Luigi De Petris; Lena Kanter; Therese Juntti; Per Bergman; Boris Zhivotovsky; Rolf Lewensohn; Petra Hååg; Kristina Viktorsson Journal: Oncotarget Date: 2016-09-13